Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial

BACKGROUND: Based on studies implicating the type 2 cytokine interleukin 13 (IL-13) as a potential contributor to critical coronavirus disease 2019 (COVID-19), this trial was designed as an early phase 2 study to assess dupilumab, a monoclonal antibody that blocks IL-13 and interleukin 4 signaling,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasson, Jennifer, Donlan, Alexandra N, Ma, Jennie Z, Haughey, Heather M, Coleman, Rachael, Nayak, Uma, Mathers, Amy J, Laverdure, Sylvain, Dewar, Robin, Jackson, Patrick E H, Heysell, Scott K, Sturek, Jeffrey M, Petri, William A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361171/
https://www.ncbi.nlm.nih.gov/pubmed/35959207
http://dx.doi.org/10.1093/ofid/ofac343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361171/
https://www.ncbi.nlm.nih.gov/pubmed/35959207
http://dx.doi.org/10.1093/ofid/ofac343

Ejemplares similares